

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or solicitation of an offer to acquire, purchase or subscribe for securities or an invitation to enter into an agreement to do any such things, nor is it calculated to invite any offer to acquire, purchase or subscribe for any securities.



维亚生物科技控股集团
VIVA BIOTECH HOLDINGS

(Incorporated in the Cayman Islands as an exempted company with limited liability)

(Stock code: 1873)

COMPLETION OF THE CSRC POST-ISSUE FILING IN RELATION TO THE ISSUE OF CONVERTIBLE BONDS

Reference is made to the announcements of Viva Biotech Holdings (the “**Company**”) dated June 11, 2023 and July 7, 2023 in relation to the issue of Convertible Bonds under the General Mandate (the “**Announcements**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

As disclosed in the Announcements, completion of the Bond Subscription took place on July 7, 2023, and the Company shall file or cause to be filed with the CSRC the CSRC Post-issue Filing within three Business Days of the date of completion. The Board is pleased to announce that the Company has recently received the notification on completion of the CSRC Post-issue Filing in relation to the issue of the Convertible Bonds.

By Order of the Board
VIVA BIOTECH HOLDINGS
MAO Chen Cheney
Chairman and Chief Executive Officer

Hong Kong, October 25, 2023

As of the date of this announcement, the Board comprises three Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying and Mr. Ren Delin; a Non-executive Director, namely, Mr. Wu Yuting; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.